SnapShot: Cancer Immunotherapy with Oncolytic Viruses

[1]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[2]  S. Gujar,et al.  Potentiating prostate cancer immunotherapy with oncolytic viruses , 2018, Nature Reviews Urology.

[3]  Lucy F. Stead,et al.  Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade , 2018, Science Translational Medicine.

[4]  J. Diallo,et al.  Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy , 2018, Science Translational Medicine.

[5]  G. Kroemer,et al.  Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. , 2017, Trends in immunology.

[6]  J. Wolchok,et al.  Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy , 2014, Science Translational Medicine.

[7]  J. Diallo,et al.  From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against Cancer , 2014, PLoS pathogens.

[8]  H. Atkins,et al.  A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  A. García-Sastre,et al.  Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.